Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML

CompletedOBSERVATIONAL
Enrollment

231

Participants

Timeline

Start Date

December 3, 2018

Primary Completion Date

May 31, 2022

Study Completion Date

May 31, 2022

Conditions
Relapsed Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaGene AbnormalityCytogenetic Abnormality
Interventions
DRUG

VAH regimen

VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-14; AZA was used at the dose of 75 mg/m2, day 1-7; HHT was given at a dose of 1mg/m2, day 1-7. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.

DRUG

VEN+HMA regimen

VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-28; AZA was used at the dose of 75 mg/m2, day 1-7 or DEC 20mg/m2 day 1-5. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.

Trial Locations (1)

510515

Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou

All Listed Sponsors
collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

collaborator

Zhongshan People's Hospital, Guangdong, China

OTHER

collaborator

Shenzhen Hospital of Southern Medical University

OTHER

collaborator

Peking University Shenzhen Hospital

OTHER

collaborator

Shenzhen Second People's Hospital

OTHER

collaborator

The Seventh Affiliated Hospital of Sun Yat-sen University

OTHER

collaborator

Southern Medical University, China

OTHER

collaborator

First People's Hospital of Chenzhou

OTHER

collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

lead

Nanfang Hospital, Southern Medical University

OTHER

NCT05456048 - Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML | Biotech Hunter | Biotech Hunter